Logo Image
News
Watch
Expert ConversationsShows & PodcastsNews & Analysis
Conferences
Conference CoverageConference Listing
Publications
Contemporary OB/GYN® JournalDigital Supplements
More
CME/CE
Resources
Physician Fact SheetsInteractive ToolsSponsored MediaSponsored ResourcesSupplements and Featured Publications
About
Partnerships

Subscribe

  • News
  • Watch
  • Conferences
  • Publications
  • CME/CE
  • Resources
  • Subscribe
  • About
  • Partnerships
  • Breast Health
  • COVID-19
  • Cervical Health
  • Contraception
  • Curbside Consults
  • Dermatology
  • Drug Pipeline News
  • Endometriosis
  • Genetic Testing
  • Gynecology
    • Gynecologic Oncology
  • Imaging
    • Fetal Imaging
    • Abnormal Obstetrical Ultrasound
    • MRI
    • Ultrasound
    • Women's Imaging
    • Breast Imaging
    • Women's Ultrasound
  • Infertility
  • LARC
  • Legally Speaking
  • Life Transitions
  • Malpractice
  • Menopause
  • Mental Health
  • Noninvasive Prenatal Testing
  • Obstetrics
  • Opinion
  • Osteoporosis
  • Pediatrics
  • Practice Management
  • Pregnancy and Birth
  • Sexual Health
  • Sexually Transmitted Infections
  • Surgery
  • Technology
  • Urology
  • Uterine Fibroids
  • Vulvovaginal Disease
  • Well Woman
Advertisement

Joy Biancosino, RN

Advertisement

Articles by Joy Biancosino, RN

Fertility Care and Severe Polycystic Ovarian Syndrome (PCOS)

ByRonald F. Feinberg, MD, PhD,Barbara A. McGuirk, MD,Joy Biancosino, RN,Ronald F. Feinberg, MD, PhD,Barbara A. McGuirk, MD,Joy Biancosino, RN,Ronald F. Feinberg, MD, PhD,Barbara A. McGuirk, MD,Joy Biancosino, RN
October 8th 2011

In women with severe clomiphene-resistant PCOS, we proposed thatthe insulin-lowering agent troglitazone (Rezulin®) could have a positive impact on the ovarian microenvironment by supporting normal follicular growth, ovulation, and successful pregnancy.

Advertisement

Latest Updated Articles

  • Fertility Care and Severe Polycystic Ovarian Syndrome (PCOS)
    Fertility Care and Severe Polycystic Ovarian Syndrome (PCOS)

    October 8th 2011



Advertisement
Advertisement

Trending on Contemporary OB/GYN

1

Centers for Medicare, Medicaid Services includes AMA's obstetric codes in 2027 fee schedule

2

FAQ: How is off-label testosterone dosed and monitored in women?

3

Mental health, bias, and trauma: Building trust in sexual medicine

4

Q&A: Soma Mandal, MD, MSCP, on FDA boxed warning removals for MHT

5

FAQ: What does the evidence show about testosterone in women?

  • Advertise
  • Contact Us
  • Job Board
  • Terms of Use
  • Privacy Policy
  • Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

  • Contagion Live
  • CGT Live
  • Neurology Live
  • HCP Live
  • Oncology Live
  • Contemporary Pediatrics
  • Contemporary OBGYN
  • Urology Times
  • The Educated Patient
  • Patient Care Online
HCP Live Network
Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us